Adaptive Design, Often Maligned



Pharma IQ
09/22/2010

When carried out well, adaptive trials not only provide evidence of safety and efficacy more quickly, but also allow you to assess that evidence and get answers earlier. In this interview John Johnson, Senior Biostatistician at Cato Research, speaks to Andrea Charles from Pharma IQ, about the three key strategies for effective use of adaptive trials in drug development and the implementation hurdles small pharma and biotech companies face. [inlinead]
TO READ THE FULL STORY